.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing recovery requires effective strategies, and using naltrexone for OUD relapse prevention is a primary clinical option. However, clinicians often face hurdles with patient adherence and treatment initiation. A comprehensive meta-analysis recently evaluated data from over 140,000 participants to identify the factors influencing these outcomes.
The study found that initiation rates vary significantly depending on the formulation. Patients initiated oral naltrexone at a rate of 60.3%, whereas only 18.2% initiated depot formulations. Notably, patients were more likely to start oral treatment when it was the only pharmacotherapy offered. This suggests that offering choices might paradoxically lower the uptake of specific treatments like naltrexone. Consequently, practitioners should carefully frame treatment options during the shared decision-making process.
Discontinuation remains a major barrier to long-term recovery. For oral naltrexone, half of the patients stopped within the first month. By the sixth month, this figure rose to 71%. Although depot formulations showed better retention initially, discontinuation still reached 60% by six months. Therefore, the first few months of treatment represent a critical window for clinical intervention. Clinicians must actively monitor patients during this period to improve long-term outcomes.
Supervised administration significantly improves retention rates for oral medication. The meta-analysis demonstrated that supervised dosing reduced discontinuation at three and six months. Specifically, supervision helps maintain the treatment bridge during vulnerable recovery phases. Therefore, incorporating family or clinical supervision can enhance the effectiveness of naltrexone for OUD relapse prevention programs. In addition, providing continuous support and counseling can further mitigate the risk of early dropout.
Many patients stop naltrexone due to a lack of immediate reinforcement, as it is an antagonist rather than an agonist. Early discontinuation is common, especially within the first month of treatment, often due to cravings or side effects during the post-withdrawal phase.
Yes, depot (injectable) formulations generally show lower discontinuation rates in the first month compared to oral naltrexone. However, both forms see significant dropout rates by the six-month mark, highlighting the need for ongoing behavioral support.
Supervised administration significantly reduces discontinuation rates. By involving a healthcare provider or a family member in the daily dosing process, patients are more likely to remain compliant, especially at the 3 and 6-month milestones.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A recent meta-analysis examine initiation and discontinuation rates of naltrexone for opioid use disorder. It highlights high early dropout rates and the significant impact of supervised administration on treatment retention for patients who have completed withdrawal.
2 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
